NYSE · Biotechnology · USD
Biohaven Ltd. (BHVN) Stock Analysis
Biohaven Ltd. (BHVN) is a Biotechnology stock listed on NYSE and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
BHVN Key Statistics
As of Oct 21, 2026Trading
- Open
- $11.90
- Previous Close
- $11.81
- Day's Range
- 11.63–12.16
- 52-Week Range
- 7.48–18.57
- Volume
- 1.44M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 3.20
Valuation
- Market Cap
- $1.71B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −4.56
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$738.82M
- Shares Outstanding
- 151.04M
- 1-Year Return
- −33.73%
Dividend and dates
- Earnings Date
- November 9, 2026estimated
- Avg Volume
- 2.62M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, BHVN closed at $11.75, −33.73% over 1 year.
Biohaven Ltd. (BHVN) has a market capitalization of $1.71B.
In fiscal 2025, BHVN reported revenue of $0.00.
BHVN Stock Return by Calendar Year
Biohaven Ltd. (BHVN) return since Sep 2022: what $10,000 became
- 1 year
- $10,000 $6,627
- −33.73%
- 3 years
- $10,000 $4,293
- −57.07%
- Since Sep 2022
- $10,000 $16,466
- +64.66%
If you had invested $10,000 in Biohaven Ltd. (BHVN) at the close on September 23, 2022, the earliest close on record here, it would have been worth $16,466 at the close on October 21, 2026: +64.66% in total, +13.01% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +4.07% |
| 2025 | −69.77% |
| 2024 | −12.73% |
| 2023 | +208.36% |
| 2022 (partial year) | +94.51% |
As of October 21, 2026.
BHVN Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$738.82M | — |
| 2024 | $0.00 | −$846.42M | — |
| 2023 | $0.00 | −$408.17M | — |
| 2022 | $0.00 | −$570.28M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$745.38M | −$738.82M | — |
| 2024 | $0.00 | — | −$885.11M | −$846.42M | — |
| 2023 | $0.00 | — | −$436.05M | −$408.17M | — |
| 2022 | $0.00 | — | −$567.93M | −$570.28M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
StocktwitsBiohaven partners with Ono in $100m IgG degrader deal
hospitalmanagement.netBiohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
BenzingaBiohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
YahooIs Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
YahooBiohaven Licenses MoDE IgG Degraders To Ono For Japan, South Korea, Taiwan And ASEAN For Up To $100M Near-Term Payments Including $80M Upfront; BHV-1300 In Phase 3 For Graves' Disease
Benzinga
All 20 articles ↓Show fewer ↑
Roche’s AI lab; Biohaven’s pivotal pause
pharmavoice.comBiohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
YahooBiohaven To Present Data On BHV-1530, FGFR3-Directed ADC Using Topoisomerase I Payload, At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
BenzingaHas Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?
YahooBiohaven’s epilepsy drug hit with FDA clinical hold
clinicaltrialsarena.comBiohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
YahooBiohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
YahooBiohaven: The Hold Isn't The Problem (Rating Downgrade)
SeekingAlphaBiohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials
InvestorsHubBHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?
StocktwitsHC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target
BenzingaFDA places partial hold on Biohaven’s epilepsy drug
BioPharma DiveFDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
BenzingaBiohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B